- Home
- NMCO vs XERS Comparison
NMCO vs XERS Comparison
Compare NMCO & XERS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NMCO
- XERS
- Stock Information
- Founded
- NMCO 2019
- XERS 2005
- Country
- NMCO United States
- XERS United States
- Employees
- NMCO N/A
- XERS N/A
- Industry
- NMCO Finance/Investors Services
- XERS Biotechnology: Pharmaceutical Preparations
- Sector
- NMCO Finance
- XERS Health Care
- Exchange
- NMCO Nasdaq
- XERS Nasdaq
- Market Cap
- NMCO 614.1M
- XERS 526.3M
- IPO Year
- NMCO N/A
- XERS 2018
- Fundamental
- Price
- NMCO $11.08
- XERS $3.75
- Analyst Decision
- NMCO
- XERS Strong Buy
- Analyst Count
- NMCO 0
- XERS 4
- Target Price
- NMCO N/A
- XERS $5.15
- AVG Volume (30 Days)
- NMCO 207.6K
- XERS 1.8M
- Earning Date
- NMCO 01-01-0001
- XERS 03-05-2025
- Dividend Yield
- NMCO 5.43%
- XERS N/A
- EPS Growth
- NMCO N/A
- XERS N/A
- EPS
- NMCO N/A
- XERS N/A
- Revenue
- NMCO N/A
- XERS $187,361,000.00
- Revenue This Year
- NMCO N/A
- XERS $25.11
- Revenue Next Year
- NMCO N/A
- XERS $19.29
- P/E Ratio
- NMCO N/A
- XERS N/A
- Revenue Growth
- NMCO N/A
- XERS 22.72
- 52 Week Low
- NMCO $8.52
- XERS $1.69
- 52 Week High
- NMCO $11.64
- XERS $4.10
- Technical
- Relative Strength Index (RSI)
- NMCO 55.12
- XERS 57.32
- Support Level
- NMCO $11.00
- XERS $3.51
- Resistance Level
- NMCO $11.24
- XERS $4.10
- Average True Range (ATR)
- NMCO 0.11
- XERS 0.17
- MACD
- NMCO -0.01
- XERS 0.03
- Stochastic Oscillator
- NMCO 43.57
- XERS 46.15
About NMCO Nuveen Municipal Credit Opportunities Fund
Nuveen Municipal Credit Opps Fund is a closed-end fund. The fund's objective is to provide a high level of current income exempt from regular U.S. federal income tax and secondarily, total return. It invests in high yielding, low-to medium-quality municipal securities and uses leverage.
About XERS Xeris Biopharma Holdings Inc.
Xeris Biopharma Holdings Inc is a biopharmaceutical company developing and commercializing unique therapies for patient populations in endocrinology, neurology, and gastroenterology. The company has three commercially available products, Gvoke, ready-to-use liquid glucagon for the treatment of severe hypoglycemia, Keveyis, the first FDA-approved therapy for primary periodic paralysis, and Recorlev, approved by the FDA for the treatment of endogenous hypercortisolemia in adult patients with Cushing's Syndrome. The Company also has a pipeline of development programs to bring new products forward using its proprietary formulation science, XeriSol and XeriJect.